Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Moulin

Showing results (111-120 of 121) with videos related to

Pageof 13
Sort By:
Clinical Pharmacology and Therapeutics|April 16, 2010
Optimization of initial tacrolimus dose using pharmacogenetic testingE Thervet, M A Loriot, S Barbier, et al.
Journal of Transplantation|May 16, 2014
Three-year outcomes in kidney transplant patients randomized to steroid-free immunosuppression or steroid withdrawal, with enteric-coated mycophenolate sodium and cyclosporine: the infinity studyA Thierry, G Mourad, M Büchler, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|November 19, 2016
Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized StudyP Gatault, N Kamar, M Büchler, et al.
Transplantation Proceedings|November 23, 2006
Tolerability of enteric-coated mycophenolate sodium to 1 year in combination with cyclosporine and corticosteroids in renal transplant recipientsL Rostaing, G Mourad, N Kamar, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|January 16, 2015
Kidney transplant recipients carrying the CYP3A4*22 allelic variant have reduced tacrolimus clearance and often reach supratherapeutic tacrolimus concentrationsN Pallet, A-S Jannot, M El Bahri, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|September 7, 2016
Predictive Modeling of Tacrolimus Dose Requirement Based on High-Throughput Genetic ScreeningC Damon, M Luck, L Toullec, et al.
Transplantation Proceedings|March 15, 2000
Could steroids be withdrawn in renal transplant patients sequentially treated with ATG, cyclosporine, and cellcept? One-year results of a double-blind, randomized, multicenter study comparing normal dose versus low-dose and withdrawal of steroids. M 55002 French Study GroupY Lebranchu, P Aubert, F Bayle, et al.
Transplantation Proceedings|August 1, 1997
An open multicenter trial of conversion from Sandimmun to Neoral in stable kidney-transplant patientsM Hourmant, C Antoine, F Bayle, et al.
Lupus|February 14, 2009
European consensus statement on the terminology used in the management of lupus glomerulonephritisC Gordon, D Jayne, C Pusey, et al.
The New England Journal of Medicine|June 7, 2013
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndromeC M Legendre, C Licht, P Muus, et al.
Pageof 13

Showing results (111-120 of 121) with videos related to

Sort By:
Pageof 13
Clinical Pharmacology and Therapeutics|April 16, 2010
Optimization of initial tacrolimus dose using pharmacogenetic testingE Thervet, M A Loriot, S Barbier, et al.
Journal of Transplantation|May 16, 2014
Three-year outcomes in kidney transplant patients randomized to steroid-free immunosuppression or steroid withdrawal, with enteric-coated mycophenolate sodium and cyclosporine: the infinity studyA Thierry, G Mourad, M Büchler, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|November 19, 2016
Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized StudyP Gatault, N Kamar, M Büchler, et al.
Transplantation Proceedings|November 23, 2006
Tolerability of enteric-coated mycophenolate sodium to 1 year in combination with cyclosporine and corticosteroids in renal transplant recipientsL Rostaing, G Mourad, N Kamar, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|January 16, 2015
Kidney transplant recipients carrying the CYP3A4*22 allelic variant have reduced tacrolimus clearance and often reach supratherapeutic tacrolimus concentrationsN Pallet, A-S Jannot, M El Bahri, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|September 7, 2016
Predictive Modeling of Tacrolimus Dose Requirement Based on High-Throughput Genetic ScreeningC Damon, M Luck, L Toullec, et al.
Transplantation Proceedings|March 15, 2000
Could steroids be withdrawn in renal transplant patients sequentially treated with ATG, cyclosporine, and cellcept? One-year results of a double-blind, randomized, multicenter study comparing normal dose versus low-dose and withdrawal of steroids. M 55002 French Study GroupY Lebranchu, P Aubert, F Bayle, et al.
Transplantation Proceedings|August 1, 1997
An open multicenter trial of conversion from Sandimmun to Neoral in stable kidney-transplant patientsM Hourmant, C Antoine, F Bayle, et al.
Lupus|February 14, 2009
European consensus statement on the terminology used in the management of lupus glomerulonephritisC Gordon, D Jayne, C Pusey, et al.
The New England Journal of Medicine|June 7, 2013
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndromeC M Legendre, C Licht, P Muus, et al.
Pageof 13